Trombólisis para la trombosis venosa profunda aguda de miembros superiores
Appendices
Appendix 1. CENTRAL search strategy
| #1 | MESH DESCRIPTOR Upper Extremity Deep Vein Thrombosis EXPLODE ALL TREES | 13 |
| #2 | MESH DESCRIPTOR Axillary Vein EXPLODE ALL TREES | 24 |
| #3 | MESH DESCRIPTOR Subclavian Vein EXPLODE ALL TREES | 95 |
| #4 | MESH DESCRIPTOR Thoracic Outlet Syndrome EXPLODE ALL TREES | 14 |
| #5 | UEDVT:TI,AB,KY | 3 |
| #6 | Paget*:TI,AB,KY | 189 |
| #7 | (upper near6 thromb*):TI,AB,KY | 68 |
| #8 | (arm near6 thromb*):TI,AB,KY | 308 |
| #9 | (central venous near6 thromb*):TI,AB,KY | 69 |
| #10 | (arm near3 clot*):TI,AB,KY | 17 |
| #11 | effort near3 thromb* | 2 |
| #12 | (subclavian near2 thromb*):TI,AB,KY | 32 |
| #13 | (thoracic and outlet):TI,AB,KY | 26 |
| #14 | (thoracic and outlet):TI,AB,KY | 26 |
| #15 | #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 | 780 |
| #16 | MESH DESCRIPTOR Thrombolytic Therapy EXPLODE ALL TREES | 1535 |
| #17 | MESH DESCRIPTOR Fibrinolytic Agents EXPLODE ALL TREES | 11015 |
| #18 | MESH DESCRIPTOR Fibrinolysis EXPLODE ALL TREES | 945 |
| #19 | MESH DESCRIPTOR Plasminogen Activators EXPLODE ALL TREES | 2240 |
| #20 | (plasminogen near2 activator* ):TI,AB,KY | 3667 |
| #21 | (tPA or t‐PA or rtPA or rt‐PA):TI,AB,KY | 2183 |
| #22 | (thromboly* or fibrinoly* or antithrombotic or antithrombic):TI,AB,KY | 8922 |
| #23 | (recanalis* or recanaliz*):TI,AB,KY | 1016 |
| #24 | (((clot* or thrombus) near3 (lyse or lysis or dissolve* or dissolution))):TI,AB,KY | 913 |
| #25 | urokinase:TI,AB,KY | 808 |
| #26 | alteplase :TI,AB,KY | 704 |
| #27 | reteplase:TI,AB,KY | 112 |
| #28 | tenecteplase:TI,AB,KY | 153 |
| #29 | saruplase:TI,AB,KY | 33 |
| #30 | anistreplase:TI,AB,KY | 156 |
| #31 | monteplase:TI,AB,KY | 14 |
| #32 | streptokinase:TI,AB,KY | 1294 |
| #33 | staphylokinase:TI,AB,KY | 17 |
| #34 | (avelizin or awelysin):TI,AB,KY | 0 |
| #35 | (celiase or distreptase or Kabikinase or kabivitrum):TI,AB,KY | 12 |
| #36 | (Streptase or streptodecase or apsac or Abbokinase or renokinase ):TI,AB,KY | 110 |
| #37 | (Actilyse or Activase or Eminase or Retavase or Rapilysin or desmopletase or u‐pa or alfimeprase ):TI,AB,KY | 89 |
| #38 | (streptodornase ):TI,AB,KY | 50 |
| #39 | (pro?urokinase or rpro?uk ):TI,AB,KY | 44 |
| #40 | (lumbrokinase or duteplase or lanoteplase or pamiteplase):TI,AB,KY | 45 |
| #41 | #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 | 19114 |
| #42 | #15 and #41 | 71 |
Appendix 2. Clinical trials database searches
ClinicalTrials.gov
66 studies found for: arm and thrombolysis
67 studies found for: upper extremity and thrombolysis
0 studies for: paget schroetter
World Health Organization International Clinical Trials Registry
12 records for 8 trials found for: arm and thrombolysis
12 records for 8 trials found for: upper extremity and thrombolysis
0 studies for: paget schroetter
ISRCTN register
15 results arm and thrombolysis
No results found for "upper extremity and thrombolysis"
No results found for "paget schroetter"
Appendix 3. Glossary
Diversity‐adjusted required information size: this term relates to trial sequential analysis (see below). When performing a trial sequential analysis, you must calculate how much information is needed before you can make conclusions with confidence. The information size is diversity adjusted, meaning that, based on how much the trials differ between each other, we will require more or less information before we are confident in our results.
Patency (of a vessel): the degree of openness of a vessel (artery or vein). A vessel with a high patency is only blocked minimally and blood flows freely through the vessel.
Random‐effects model: a statistical model of how to meta‐analyse (pool or combine) study results. It can be seen as an alternative to the fixed‐effect model. It is a way of stating how will you weigh the results of small trials compared with the results from larger trials. There are different kinds of random‐effects models available for use.
Trial sequential analysis: an analysis that attempts to assess how robust the conclusions from your data are. Some people argue that it is a more sound statistical test than using the traditional P value that is often used in medical literature.
Study flow diagram.
